LLY · Eli Lilly and Co
Price
Snapshot
50 fields · last close| Market Cap | $1.18T |
| P/E | 44.30 |
| Float | 939.7M |
| Beta | 0.42 |
| Volatility | 10.4% |
| Exchange | NYSE |
| Sector | Pharmaceuticals |
| Cap tier | Mega cap |
| Macro sensitivity | Low |
| Clavix score | 75.0 |
| Price | 1,248.52 |
| Change | −0.68% |
| Prev Close | 1,257.03 |
| Open | 1,256.00 |
| Day Low | 1,251.25 |
| Day High | 1,274.56 |
| Avg Vol | 2 |
| Avg $ Vol | $2.93B |
| 52W High | 1,292.65 |
| 52W Low | 783.85 |
| 52W Pos | 91.3% |
| From High | −3.41% |
| From Low | +59.28% |
| Max DD 1Y | −23.31% |
| Spread | 0.10% |
| Liquidity | Deep |
| SMA 20 | +5.92% |
| SMA 50 | +5.78% |
| SMA 200 | +15.61% |
| RSI (14) | 68.6 |
| Vol 30D | 24.0% |
| Vol 90D | 30.6% |
| 1Y Range | 784–1,293 |
| Daily bars | 536 |
| Perf Week | +6.59% |
| Perf Month | +9.08% |
| Perf Quarter | +9.60% |
| Perf Half Y | +35.60% |
| Perf Year | +52.08% |
| Perf YTD | +15.57% |
| Prev Day | −0.68% |
| Clavix | B |
| Debt / Eq | 1.11 |
| Curr Ratio | 1.58 |
| Int Cover | 35.7× |
| FCF Margin | 25.8% |
| Rev Growth | +44.7% |
| Profit | Profitable |
| Leverage | High |
| Sector rank | 10 / 14 |
What LLY does
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally.
The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin’s lymphoma; and Verzenio for breast cancer.
In addition, the company offers immunology products, which include Ebglyss for severe atopic dermatitis; Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Omvoh for ulcerative colitis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis.
Further, it provides Emgality for migraine prevention and episodic cluster headache, as well as Kisubla for symptomatic Alzheimer’s disease.
The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F.
Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron; strategic collaboration with Ascidian Therapeutics for development of therapies for undisclosed monogenic kidney diseases; and BioArctic AB (publ) for new treatment.
Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Clavix risk grade
regraded every trading dayLLY grades B, 75.0 of 100. Steadiest on Macro Resilience (69), most exposed on News Sentiment (45, fragile). 1 of the 4 weighted dimensions sit above the Pharmaceuticals median. Ranks 10 of 14 in Pharmaceuticals by Clavix score.
How rough the ride is
| LLY | Pharmaceuticals median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 0.42 | 0.44 |
| Volatilityannualized | 10.4% | 10.9% |
| Max drawdown, past yearworst peak-to-trough fall | −23.3% | — |
| Typical daily movemedian absolute daily change | 1.26% | — |
| Days beyond ±3%of the last 252 sessions | 33 (13%) | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| LLY | Pharmaceuticals median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 0.42 | 0.44 |
| Macro sensitivityrate, dollar and credit exposure bucket | Low | Low 67% of 15 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Pharmaceuticals names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| LLY | |
|---|---|
| 1 week | +6.6% |
| 1 month | +9.1% |
| Year to date | +15.6% |
| 1 year | +52.1% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| LLY | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30 since 7 Oct |
| Average score0 most bearish, 100 most bullish | 66 |
| Bullish · bearisharticles above 60 · below 40 | 23 · 3 |
| Directionarticles whose tone is improving vs worsening | 23 ↑ 3 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 15 Pharmaceuticals names Clavix covers; the tick is the sector median.
Growth
| LLY | |
|---|---|
| Revenue growthyear over year | +44.7% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Pharmaceuticals median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Recent news
most recent scored articles · the chip is the article’s score · click to openHong Kong-listed Metis TechBio said it entered a collaboration agreement with Eli Lilly worth up to $1.1 billion to research and develop technologies that deliver drugs to specific tissues in the body, rather than throughout the whole system.
Eli Lilly announced that its drug Omvoh met its primary goal in a Phase 3 pediatric ulcerative colitis trial, with 81% of patients ages 6 to 17 responding to induction and roughly half of those responders in clinical remission after one year. The company plans to submit the data to regulators worldwide to seek approval for use in children.
Eli Lilly's weight-loss pill Foundayo received backing from the EU's drug regulator on October 16, moving the company closer to selling the pill in Europe. The article also flags an upcoming October 29 date, suggesting LLY will share results or an update on Foundayo then. Stock price targets cited are analyst views, not company news.
Research firm Wall Street Zen lowered its rating on Eli Lilly from 'buy' to 'hold' in a report released on Saturday. The article provides no further details or reasoning for the downgrade.
An article discusses three newer drugs beyond weight-loss treatment Zepbound, specifically naming Foundayo and retatrutide, as potential drivers of Eli Lilly's next phase of growth. It also notes that the company's latest approval has strengthened its diabetes business.
Nearest peers by size
Pharmaceuticals| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| JNJ | Johnson & Johnson | A- | $615.9B | 38.26 | 0.21 | Compare |
| MRK | Merck & Co Inc | B+ | $360.1B | 113.48 | 0.12 | Compare |
| AZN | AstraZeneca PLC | B+ | $196.9B | 25.12 | 1.27 | Compare |
| PFE | Pfizer Inc | A- | $168.6B | 38.91 | 0.31 | Compare |
| BMY | Bristol-Myers Squibb Co | B+ | $122.1B | 13.15 | 0.19 | Compare |
| RPRX | Royalty Pharma PLC | A | $35.06B | 43.01 | 0.39 | Compare |
| ZTS | Zoetis Inc | B+ | $31.87B | 12.55 | 0.70 | Compare |
| VTRS | Viatris Inc | B+ | $21.43B | — | 0.89 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. 1 month free on iPhone.